Clinical trial · Observational
18F-Pentixafor PET in Hematologic Malignancies
Prospective Clinical Study of 18F-Pentixafor PET Imaging in Hematologic Malignancies
NCT07122674CI-TRIAL-00093660recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the efficacy of 18F-Pentixafor PET imaging in the diagnosis, staging and response evaluation of hematological malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematological Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-Pentixafor | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 18F-Pentixafor PET/CT in Hematologic Malignancies
- description
- Each patient receive a single intravenous injection of 18F-Pentixafor 55 MBq/kg and undergo PET/CT or PET/MR scan after 60 min post-injection.
- interventionNames
- Drug: 18F-Pentixafor
Primary outcomes (1)
- measure
- Diagnostic efficacy
- timeFrame
- through study completion, an average of 1.5 year
- description
- Sensitivity, specificity, positive and negative predictive value of 18F-Pentixafor PET/CT and PET/MR Imaging in hematological malignancies.
Secondary outcomes (2)
- measure
- 18F-Pentixafor PET performence compared with 18F-FDG
- timeFrame
- up to 24 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age of 18-80 years old, both sexes, with behavioral capacity; 2. patients with suspected or confirmed hematological malignancies; 3. 18F-FDG PET or other imaging examinations should be performed according to the treatment plan; 4. For suspected patients, biopsy or needle biopsy is expected to obtain pathological results; 5. Can provide informed consent, can understand and comply with the requirements of the study. Exclusion Criteria: 1. pregnant and lactating women; 2. patients with fear or radiophobia, or with mental disorder or primary affective disorder; 3. received ionizing radiation outside the scope of this study for clinical medical or scientific research purposes within the past year, resulting in an annual radiation exposure dose exceeding 50 mSv; 4. received investigational drugs or devices of uncertain efficacy or safety within 1 month; 5. Any condition that the chairpersons of the study consider that any link related to the study may cause harm or have potential harm.
References
Publications (0)
Data not yet available
No reference posted for this study.